Volume : VIII, Issue : II, February - 2019
New frontiers in Community Acquired pneumonia: Garenoxacin mesylate
Payel Bhattacharji, Krishnaprasad Korukonda, Hanmant Barkate, Janani Mishma
Abstract :
Garenoxacin mesylate is a novel des–fluoro (6) quinolone with unique Pharmacokinetic profile that promises to cover a wide spectrum of sensitive and resistant organisms commonly encountered in community acquired infections including PRSP or BLNAR strains. Garenoxacin has been structurally designed to ensure high potency against Gm positive, Atypical & Anaerobic organisms with negligible potential for resistance development. Garenoxacin approved in the worldwide market since 2007 has been documented in over 10,000 patients with community acquired respiratory tract infections or Community–acquired Pneumonia when used as initial– or second–line therapy
Keywords :
Article:
Download PDF
DOI : 10.36106/ijsr
Cite This Article:
NEW FRONTIERS IN COMMUNITY ACQUIRED PNEUMONIA: GARENOXACIN MESYLATE, Payel Bhattacharji, Krishnaprasad Korukonda, Hanmant Barkate, Janani Mishma INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH : Volume-8 | Issue-2 | February-2019
Number of Downloads : 246
References :
NEW FRONTIERS IN COMMUNITY ACQUIRED PNEUMONIA: GARENOXACIN MESYLATE, Payel Bhattacharji, Krishnaprasad Korukonda, Hanmant Barkate, Janani Mishma INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH : Volume-8 | Issue-2 | February-2019
Our Other Journals...
-
Indian Journal of
Applied Research Visit Website -
PARIPEX Indian Journal
of Research Visit Website -
Global Journal for
Research Analysis Visit Website